Cardarine
Cardarine (GW-501516)
100 tabs × 20 mg/tab
Coming soon
View details Cardarine (GW-501516) →Product photograph of the current pack. Each physical unit carries the same blue-teal ZX label artwork, a batch code and a scratch-off verification panel.
Selective Androgen Receptor Modulators
Ibutamoren
Independent batch results for Ibutamoren (MK 677) are not yet published. They will be added here once testing is complete.
Product information
25 mg per tablet · 100 tablets · Zyvex Pharmaceuticals
Ibutamoren (MK 677) from Zyvex Pharmaceuticals contains ibutamoren at 25 mg per tablet and comes in a pack of 100 tablets.
This prospect summarises composition, clinical considerations and handling. It supports professional review and does not replace an individual prescription or verified instructions for the exact preparation.
Ibutamoren (MK 677) is the product name used by Zyvex Pharmaceuticals. The ingredient discussed in the following sections is ibutamoren, classified as a ghrelin-receptor agonist and growth-hormone secretagogue.
| Property | Details |
|---|---|
| Product name | Ibutamoren (MK 677) |
| Manufacturer | Zyvex Pharmaceuticals |
| Active ingredient | Ibutamoren |
| Strength | 25 mg per tablet |
| Package | 100 tablets |
| Drug class | Ghrelin-receptor agonist and growth-hormone secretagogue |
| Chemical formula | C27H36N4O5S (free base) |
| Dosage form and route | Tablet; oral |
A solid tablet for oral administration. Each tablet provides a measured amount of active ingredient. Confirm suitability with a pharmacist before splitting or crushing; appearance and score lines alone do not establish accurate dose division.
Ibutamoren (MK 677) from Zyvex Pharmaceuticals contains ibutamoren. Ibutamoren stimulates growth-hormone secretion and has been studied for age-related changes in body composition. Research on fat-free mass does not by itself demonstrate treatment of frailty or improved daily function.
People seek ibutamoren for muscle gain, appetite and perceived recovery or anti-ageing effects. These goals should be distinguished from measured clinical benefits.
A controlled trial in adults aged 60–81 used 25 mg orally once daily, with primary outcomes after one year. Fat-free mass increased, but strength and function did not improve; glucose and insulin-sensitivity changes also occurred. This research schedule does not establish a safe bodybuilding or wellbeing protocol.
A reliable routine human dosing regimen cannot be established from the available clinical evidence. The product strength must not be converted into a self-treatment schedule. Human use requires an appropriately supervised clinical or research setting with a defined protocol. A 25 mg research dose appearing in a trial does not establish that this tablet is appropriate for unsupervised treatment.
A complete clinical contraindication profile has not been established. Avoid exposure with known hypersensitivity, during pregnancy or breastfeeding, and in children outside a properly reviewed clinical setting. Absence of a listed contraindication is not evidence of safety. Diabetes, impaired glucose tolerance, oedema and heart failure warrant particular clinical attention.
Ibutamoren can increase glucose and reduce insulin sensitivity. Fluid retention is a concern; heart-failure risk has been raised in clinical safety reviews. Review fasting glucose, symptoms of swelling and cardiometabolic history before any research exposure.
Human interaction studies are limited. A clinician or study team should review all prescription medicines, nonprescription products and supplements. There is no basis for assuming that combinations with other experimental compounds are safe. Medicines for diabetes and other agents affecting growth-hormone signalling deserve specific review.
Adequate pregnancy, lactation and reproductive safety evidence is lacking. Avoid exposure during pregnancy or breastfeeding. Any reproductive-risk precautions in a clinical study should be directed by the study team.
Trials have reported increased appetite, lower-limb swelling and muscle pain, alongside changes in glucose regulation. Improvement in a laboratory hormone level does not mean that physical function or long-term health improves.
For a suspected overdose, contact a poison-information service or urgent medical care and provide the product, amount, time and other substances taken. Collapse, seizures or breathing difficulty require emergency help. Do not induce vomiting or attempt an antidote at home. Clinical treatment depends on symptoms and the substances involved.
Ibutamoren stimulates the ghrelin receptor and promotes endogenous growth-hormone release, with downstream increases in IGF-1. It is a nonpeptide compound, distinct from injected growth hormone and from SARMs.
Ibutamoren is orally active. The duration of growth-hormone and IGF-1 changes is not the same measurement as plasma drug half-life. Trial pharmacology cannot establish the dose or bioequivalence of this particular tablet.
Keep tablets sealed in the original container, protected from excessive heat, moisture and accidental access. Use storage and expiry conditions supported by the finished preparation's stability information. A laboratory compound's storage temperature does not establish appropriate medicinal tablet storage. Arrange disposal through a pharmacy or supervising research service.
Browse more
Cardarine
100 tabs × 20 mg/tab
Coming soon
View details Cardarine (GW-501516) →